Pacific Biosciences of California (PACB) 10-Q 5 May 15 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 30, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	PACB
Entity Registrant Name	PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Entity Central Index Key	1299130
Current Fiscal Year End Date	-19
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		74,565,783

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets
Cash and cash equivalents	$30,271	$36,449
Investments	48,878	64,899
Accounts receivable	5,287	3,406
Inventory	13,457	11,335
Prepaid expenses and other current assets	1,629	1,671
Total current assets	99,522	117,760
Property and equipment, net	6,743	6,601
Other long-term assets	156	162
Total assets	106,421	124,523
Current liabilities
Accounts payable	6,924	5,608
Accrued expenses	9,438	11,441
Deferred service revenue, current	6,254	6,121
Deferred contractual revenue, current	14,385	6,785
Other liabilities, current	1,410	1,534
Total current liabilities	38,411	31,489
Deferred service revenue, non-current	1,605	1,129
Deferred contractual revenue, non-current	8,539	19,735
Other liabilities, non-current	2,192	2,153
Notes payable	14,339	14,124
Financing derivative	863	944
Total liabilities	65,949	69,574
Commitments and contingencies
Stockholders' equity
Preferred Stock, $0.001 par value: Authorized 50,000 shares; No shares issued or outstanding
Common Stock, $0.001 par value: Authorized 1,000,000 shares; Issued and outstanding 74,542 shares at March 31, 2015 and 73,927 shares at December 31, 2014	75	74
Additional paid-in-capital	742,027	736,339
Accumulated other comprehensive income	16	9
Accumulated deficit	-701,646	-681,473
Total stockholders' equity	40,472	54,949
Total liabilities and stockholders' equity	$106,421	$124,523

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Condensed Consolidated Balance Sheets [Abstract]
Preferred Stock, par value	$0.00	$0.00
Preferred Stock, shares authorized	50,000,000	50,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value	$0.00	$0.00
Common Stock, shares authorized	1,000,000,000	1,000,000,000
Common Stock, shares issued	74,542,000	73,927,000
Common Stock, shares outstanding	74,542,000	73,927,000

Condensed_Consolidated_Stateme

Condensed Consolidated Statements Of Operations And Comprehensive Loss (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Revenue:
Product revenue	$11,308	$7,865
Service and other revenue	2,741	2,081
Contractual revenue	3,596	1,696
Total revenue	17,645	11,642
Cost of Revenue:
Cost of product revenue	9,732	7,169
Cost of service and other revenue	1,986	1,797
Total cost of revenue	11,718	8,966
Gross profit	5,927	2,676
Operating Expense:
Research and development	14,483	11,771
Sales, general and administrative	10,772	9,150
Total operating expense	25,255	20,921
Operating loss	-19,328	-18,245
Interest expense	-697	-686
Other income (expense), net	-148	45
Net loss	-20,173	-18,886
Other comprehensive income (loss):
Unrealized gain on investments	7	4
Comprehensive loss	($20,166)	($18,882)
Net loss per share:
Basic and diluted net loss per share	($0.27)	($0.28)
Shares used in computing basic and diluted net loss per share	74,149	67,861

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements Of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities
Net loss	($20,173)	($18,886)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	908	1,221
Amortization of debt discount and financing costs	220	182
Stock-based compensation	3,255	2,270
Other items	-69	20
Changes in assets and liabilities
Accounts receivable	-1,881	-637
Inventory	-2,122	1,749
Prepaid expenses and other assets	43	-507
Accounts payable	983	2,209
Accrued expenses	-2,003	-1,489
Deferred service revenue	609	258
Deferred contractual revenue	-3,596	-1,696
Other liabilities	-85	-950
Net cash used in operating activities	-23,911	-16,256
Cash flows from investing activities
Purchase of property and equipment	-717	-477
Purchase of investments	-25,265	-36,515
Sales of investments	6,817
Maturities of investments	34,464	45,190
Net cash provided by investing activities	15,299	8,198
Cash flows from financing activities
Proceeds from issuance of common stock from equity plans	2,434	2,311
Proceeds from issuance of common stock from at-the-market equity offering, net of issuance costs		20,646
Net cash provided by financing activities	2,434	22,957
Net increase (decrease) in cash and cash equivalents	-6,178	14,899
Cash and cash equivalents at beginning of period	36,449	26,362
Cash and cash equivalents at end of period	$30,271	$41,261

Overview

Overview	3 Months Ended
	Mar. 31, 2015
Overview [Abstract]
Overview	NOTE 1. OVERVIEW
	Pacific Biosciences of California, Inc., (“Pacific Biosciences”, the “Company”, “we”, “us”) has commercialized the PacBio RS II High Resolution Genetic Analyzer to help scientists solve genetically complex problems. Based on our novel Single Molecule, Real-Time (SMRT®) technology, our products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. Our technology combines very high consensus accuracy and long read lengths with the ability to detect real-time kinetic information.
	The names “Pacific Biosciences,” “PacBio,” “SMRT,” “SMRTbell” and our logo are our trademarks.

Summary_Of_Significant_Account

Summary Of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Summary Of Significant Accounting Policies [Abstract]
Summary Of Significant Accounting Policies	NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Basis of Presentation
	In the opinion of management, the accompanying unaudited Condensed Consolidated Financial Statements (“Financial Statements”) of Pacific Biosciences of California, Inc. have been prepared on a consistent basis with our December 31, 2014 audited Consolidated Financial Statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. Certain prior year amounts in the Financial Statements and notes thereto have been reclassified to conform to the current year presentation. The Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) and, as permitted by such rules and regulations, omit certain information and footnote disclosures necessary to present the statements in accordance with U.S. generally accepted accounting principles (“GAAP”). These Financial Statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014.  The results of operations for the three-month period ended March 31, 2015 are not necessarily indicative of the results to be expected for the entire 2015 fiscal year or any future periods.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. Our estimates include, but are not limited to, the valuation of inventory, revenue valuation, the valuation of financing derivative and long-term notes, the valuation and recognition of share-based compensation, the valuation of warrants, the delivery period for collaboration agreements, the useful lives assigned to long-lived assets, and the computation provisions for income taxes. Actual results could differ materially from these estimates.
	During the three-month period ended March 31, 2015 we revised the service period related to our contractual revenue amortization based on increasing certainty of the development time on a prospective approach. As a result, we will, on a prospective basis, recognize the remaining deferred contractual revenue associated with upfront payment received under the Roche Agreement over the revised estimated remaining development period. There have been no other material changes to our critical accounting policies and estimates discussed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014.
	Fair Value of Financial Instruments
	Assets and liabilities measured at fair value on a recurring basis
	The following table sets forth the fair value of our financial assets and liabilities measured on a recurring basis as of March 31, 2015 and December 31, 2014:
	(in thousands)	31-Mar-15										31-Dec-14
		Level 1			Level 2			Level 3		Total		Level 1		Level 2		Level 3		Total
	Assets
	Cash and cash equivalents:
	Cash and money market funds	$	9,799		$	—		$	—	$	9,799	$	21,952	$	—	$	—	$	21,952
	Commercial paper		—			20,472			—		20,472		—		14,497		—		14,497
	Total cash and cash equivalents		9,799			20,472			—		30,271		21,952		14,497		—		36,449
	Investments:
	Commercial paper		—			24,953			—		24,953		—		43,653		—		43,653
	Corporate debt securities		—			8,149			—		8,149		—		8,173		—		8,173
	Asset backed securities		—			15,776			—		15,776		—		13,073		—		13,073
	Total investments		—			48,878			—		48,878		—		64,899		—		64,899
	Total assets measured at fair value	$	9,799		$	69,350		$	—	$	79,149	$	21,952	$	79,396	$	—	$	101,348
	Liabilities
	Financing derivative	$	—		$	—		$	863	$	863	$	—	$	—	$	944	$	944
	Our cash deposits and money market funds are classified within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. Our investments are classified as Level 2 instruments based on market pricing and other observable inputs. None of our investments are classified within Level 3 of the fair value hierarchy.
	During the three-month periods ended March 31, 2015 and 2014, there were no impairments of our investments.
	The estimated fair value of the Financing Derivative liability (as defined in Note 6. Notes Payable) was determined using Level 3 inputs, or significant unobservable inputs. Changes to the estimated fair value of the Financing Derivative are recorded in “Other income (expense), net” in the condensed consolidated statements of operations and comprehensive loss. The following table provides the changes in the estimated fair value of the Financial Derivative during the three-month period ended March 31, 2015 (in thousands):
	Financial Derivative	Amount
	Balance as of December 31, 2014	$	944
	Gain on change in estimated fair value		-81
	Balance as of March 31, 2015	$	863
	During the three-month period ended March 31, 2015 there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis and valuation techniques did not change compared to established practice.
	Financial assets and liabilities not measured at fair value on a recurring basis
	The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities. The carrying value of our other liabilities, non-current, approximates fair value due to the time to maturity and prevailing market rates.
	We determined the estimated fair value of the Notes (as defined in Note 6. Notes Payable) from the debt facility using Level 3 inputs, or significant unobservable inputs. The estimated fair value of the Notes was determined by comparing the difference between the estimated fair value of the Notes with and without the Financing Derivative by calculating the respective present values from future cash flows using an 18.4% and 19.5% weighted average market yield at March 31, 2015 and December 31, 2014, respectively.
	The estimated fair value and carrying value of the Notes are as follows (in thousands):
		31-Mar-15						31-Dec-14
		Fair Value			Carrying Value			Fair Value		Carrying Value
	Long-term notes payable	$	15,210		$	14,339		$	14,817	$	14,124
	Net Loss per Share
	The following table presents the computation of our basic and diluted net loss per share (in thousands, except per share amounts):
			Three-Month Periods Ended March 31,
			2015			2014
	Net loss per share
	Numerator:
	Net loss		$	-20,173		$	-18,886
	Denominator:
	Weighted average shares used in computation of basic and diluted net loss per share			74,149			67,861
	Basic and diluted net loss per share		$	-0.27		$	-0.28
	The following were excluded from the computation of our diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect:
		As of March 31,
	(in thousands)	2015		2014
	Options outstanding	18,796		15,714
	Warrants to purchase common stock	5,500		5,500
	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2014-09, Revenue from Contracts with Customers, requiring entities to recognize revenue to which it expects to be entitled for the transfer of promised goods or services to customers.  The updated standard will replace most existing revenue recognition guidance in GAAP when it becomes effective and permits the use of either a retrospective or cumulative effect transition method. The updated standard is effective for the Company in the first quarter of fiscal year 2017 and early adoption is not permitted. We are currently in the process of evaluating the impact of adopting this ASU on our financial statements and related disclosures.
	In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This ASU introduces an explicit requirement for management to assess if there is substantial doubt about an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. Disclosures are required if conditions give rise to substantial doubt. This ASU is effective for us in the first quarter of fiscal year 2017. We are currently in the process of evaluating the impact of adopting this ASU on our financial statements and related disclosures.
	In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs,  which changes the presentation of debt issuance costs in financial statements. This ASU requires an entity to present such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs will continue to be reported as interest expense. This ASU is effective for the Company’s annual report periods beginning after December 15, 2016 and is effective for us in the first quarter of fiscal year 2016. Early adoption is permitted. The new guidance will be applied retrospectively to each prior period presented. We are currently in the process of evaluating the impact of adopting this ASU on our financial statements and related disclosures.

Contractual_Revenue

Contractual Revenue	3 Months Ended
	Mar. 31, 2015
Contractual Revenue [Abstract]
Contractual Revenue	NOTE 3. CONTRACTUAL REVENUE
	During September 2013, we entered into a Development, Commercialization and License Agreement (the “Roche Agreement”) with F. Hoffman-La Roche Ltd (“Roche”), pursuant to which we account for, and recognize as revenue, the up-front payment using the proportional performance method over the periods in which the delivery of elements of the agreement occurs. We recognize revenue using a straight-line convention over the service periods of the deliverables as this method approximates our performance of services pursuant to the contract. Out of the $35.0 million upfront cash payment received, quarterly amortization of $1.7 million has been recognized as contractual revenue from the fourth quarter of 2013 to the fourth quarter of 2014.
	During the three-month period ended March 31, 2015 we revised the estimated development period related to our contractual revenue amortization based on increasing certainty of the development time on a prospective approach. This change in estimate resulted in $1.9 million of additional contractual revenue being recognized in the first quarter of 2015 with a total of $3.6 million of quarterly amortization for the period.  As a result, we will, on a prospective basis, recognize the remaining deferred revenue of $22.9 million associated with upfront payment received under the Roche Agreement over the revised estimated remaining development period. This additional contractual revenue of $1.9 million had a 100% margin thus decreased our net loss by the same amount and improved our net loss per share by $0.03 per share.
	In addition to the deliverables above, the Roche Agreement provides for additional payments totaling up to $40.0 million upon the achievement of certain development milestones. During August 2014, we achieved the first development milestone and we recorded the related $10.0 million as contractual revenue. In addition, we achieved the second development milestone subsequent to March 31, 2015. Please refer to Note 8 Subsequent Event for further information.

Cash_Cash_Equivalents_And_Inve

Cash, Cash Equivalents And Investments	3 Months Ended
	Mar. 31, 2015
Cash, Cash Equivalents And Investments [Abstract]
Cash, Cash Equivalents And Investments	NOTE 4. CASH, CASH EQUIVALENTS AND INVESTMENTS
	The following table summarizes our investments as of March 31, 2015 and December 31, 2014 (in thousands):
		31-Mar-15
				Gross		Gross
		Amortized		unrealized		unrealized		Fair
		Cost		gains		losses		Value
	Cash and cash equivalents:
	Cash and money market funds	$	9,799	$	—	$	—	$	9,799
	Commercial paper		20,471		1		—		20,472
	Total cash and cash equivalents		30,270		1		—		30,271
	Investments:
	Commercial paper		24,950		3		—		24,953
	Corporate debt securities		8,138		11		—		8,149
	Asset backed securities		15,775		2		-1		15,776
	Total investments		48,863		16		-1		48,878
	Total cash, cash equivalents and investments	$	79,133	$	17	$	-1	$	79,149
		31-Dec-14
				Gross		Gross
		Amortized		unrealized		unrealized		Fair
		Cost		gains		losses		Value
	Cash and cash equivalents:
	Cash and money market funds	$	21,952	$	—	$	—	$	21,952
	Commercial paper		14,496		1		—		14,497
	Total cash and cash equivalents		36,448		1		—		36,449
	Investments:
	Commercial paper		43,648		5		—		43,653
	Corporate debt securities		8,170		7		-4		8,173
	Asset backed securities		13,073		4		-4		13,073
	Total investments		64,891		16		-8		64,899
	Total cash, cash equivalents and investments	$	101,339	$	17	$	-8	$	101,348
	The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of March 31, 2015:
	(in thousands)	Fair Value
	Due in one year or less	$	69,350
	Actual maturities may differ from contractual maturities because issuers may have the right to call or prepay obligations without call or prepayment penalties.

Inventory

Inventory	3 Months Ended
	Mar. 31, 2015
Inventory [Abstract]
Inventory	NOTE 5.  INVENTORY
	Inventory
	As of March 31, 2015 and December 31, 2014, our inventory, net, consisted of the following components:
		March 31,		December 31,
	(in thousands)	2015		2014
	Purchased materials	$	2,064	$	3,150
	Work in process		9,751		6,115
	Finished goods		1,642		2,070
	Inventory	$	13,457	$	11,335

Notes_Payable

Notes Payable	3 Months Ended
	Mar. 31, 2015
Notes Payable [Abstract]
Notes Payable	NOTE 6.  NOTES PAYABLE
	Pursuant to a Facility Agreement (the “Facility Agreement”) we entered into with entities affiliated with Deerfield Management Company, L.P. (collectively, “Deerfield”) during February 2013, we issued promissory notes in the aggregate principal amount of $20.5 million (the “Notes”). The Notes bear simple interest at a rate of 8.75% per annum, payable quarterly in arrears commencing on April 1, 2013. In connection with the execution of the Facility Agreement, we issued warrants to purchase an aggregate of 5,500,000 shares of common stock immediately exercisable at an exercise price per share initially equal to $2.63 (the “Warrants”). In addition, the Facility Agreement requires us to maintain consolidated cash and cash equivalents on the last day of each calendar quarter of not less than $2.0 million. As security for our repayment of our obligations under the Facility Agreement, we granted to Deerfield a security interest in substantially all of our property.
	Financing Derivative
	A number of features embedded in the Notes to the Facility Agreement required accounting for as a derivative, including the indemnification of certain withholding taxes and the acceleration of debt upon (i) a qualified financing, (ii) an Event of Default, (iii) a Major Transaction, and (iv) the exercise of the warrant via offset to debt principal. These features represent a single derivative (the “Financing Derivative”) that was bifurcated from the debt instrument and accounted for as a liability at fair value, with changes in fair value between reporting periods recorded in other income (expense), net.
	The estimated fair value of the Financing Derivative was determined by comparing the difference between the fair value of the Notes with and without the Financing Derivative by calculating the respective present values from future cash flows using an 18.4% and 19.5% weighted average market yield at March 31, 2015 and December 31, 2014, respectively. The estimated fair value of the Financing Derivative as of each of March 31, 2015 and December 31, 2014 was $0.9 million.
	Notes
	We initially recorded the Notes and Warrants at a value of $14.1 million and $6.4 million, respectively, based upon the relative fair value allocation of the $20.5 million of proceeds. The carrying value of the Notes at the inception of the debt was $12.8 million, resulting in an original issue discount of $7.7 million. As of March 31, 2015 and December 31, 2014,  debt discount of $6.2 million and $6.4 million remained to be amortized through February 2020, the maturity of the Notes.

Stockholders_Equity_And_ShareB

Stockholders' Equity And Share-Based Compensation	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity And Share-Based Compensation [Abstract]
Stockholders' Equity And Share-Based Compensation	NOTE 7. STOCKHOLDERS’ EQUITY AND SHARE-BASED COMPENSATION
	Warrants
	As of March 31, 2015, we had outstanding warrants to purchase an aggregate of 5,500,000 shares of common stock.
	Equity Plans
	As of March 31, 2015, we had three active equity compensation plans: the 2010 Equity Incentive Plan, the 2010 Outside Director Equity Incentive Plan, and the 2010 Employee Stock Purchase Plan (“ESPP”).
	The following table summarizes stock option activity for all stock option plans for the three-month period ended March 31, 2015 (in thousands, except per share amounts):
				Stock Options Outstanding
								Weighted
		Shares available		Number				average
		for grant		of shares		Exercise price		exercise price
	Balances, December 31, 2014	4,874		16,491		$	0.70 – 16.00	$	5.10
	Additional shares reserved	4,435
	Options granted	-2,474		2,474			5.72 – 7.59		6.55
	Options exercised	—		-72			0.70 – 5.18		2.40
	Options canceled	97		-97			1.16 – 15.98		6.63
	Balances, March 31, 2015	6,932		18,796		$	0.70 – 16.00	$	5.30
	Shares issued under the ESPP totaled 532,217 and 1,048,604 shares during the three-month periods ended March 31, 2015 and 2014, respectively. As of March 31, 2015,  946,329 shares of our common stock remain available for issuance under our ESPP.
	Stock-based Compensation
	Total stock-based compensation expense consists of the following (in thousands):
		Three-Month Periods Ended March 31,
		2015			2014
	Cost of revenue	$	298		$	141
	Research and development		1,255			886
	Sales, general and administrative		1,702			1,243
	Total stock-based compensation expense	$	3,255		$	2,270
	We estimated the fair value of employee stock options on the grant date using the Black-Scholes option pricing model. The estimated fair value of employee stock options is amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options was estimated using the following weighted average assumptions:
		Three-Month Periods Ended March 31,
	Stock Option	2015		2014
	Expected term in years	6.1		6.1
	Expected volatility	70%		70%
	Risk-free interest rate	1.60%		1.90%
	Dividend yield	—		—
	We estimate the value of the employee stock purchase rights on the grant date using the Black-Scholes option pricing model. The fair value of ESPP was estimated using the following assumptions:
		Three-Month Periods Ended March 31,
	ESPP	2015		2014
	Expected term in years	0.5-2.0		0.5-2.0
	Expected volatility	70%		70%
	Risk-free interest rate	0.1%-0.6%		0.1%-0.3%
	Dividend yield	—		—

Subsequent_Event

Subsequent Event	3 Months Ended
	Mar. 31, 2015
Subsequent Event [Abstract]
Subsequent Event
	NOTE 8. SUBSEQUENT EVENT
	During April 2015, we achieved the second development milestone under the Roche Agreement, entitling us to a milestone payment of $10.0 million. The achievement of the development milestone will be recognized as contractual revenue for the quarter ending June 30, 2015. We may receive up to an additional $20.0 million based on additional milestone achievement in the future.

Summary_Of_Significant_Account1

Summary Of Significant Accounting Policies (Policy)	3 Months Ended
	Mar. 31, 2015
Summary Of Significant Accounting Policies [Abstract]
Basis Of Presentation	Basis of Presentation
	In the opinion of management, the accompanying unaudited Condensed Consolidated Financial Statements (“Financial Statements”) of Pacific Biosciences of California, Inc. have been prepared on a consistent basis with our December 31, 2014 audited Consolidated Financial Statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. Certain prior year amounts in the Financial Statements and notes thereto have been reclassified to conform to the current year presentation. The Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) and, as permitted by such rules and regulations, omit certain information and footnote disclosures necessary to present the statements in accordance with U.S. generally accepted accounting principles (“GAAP”). These Financial Statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014.  The results of operations for the three-month period ended March 31, 2015 are not necessarily indicative of the results to be expected for the entire 2015 fiscal year or any future periods.
Use Of Estimates	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. Our estimates include, but are not limited to, the valuation of inventory, revenue valuation, the valuation of financing derivative and long-term notes, the valuation and recognition of share-based compensation, the valuation of warrants, the delivery period for collaboration agreements, the useful lives assigned to long-lived assets, and the computation provisions for income taxes. Actual results could differ materially from these estimates.
	During the three-month period ended March 31, 2015 we revised the service period related to our contractual revenue amortization based on increasing certainty of the development time on a prospective approach. As a result, we will, on a prospective basis, recognize the remaining deferred contractual revenue associated with upfront payment received under the Roche Agreement over the revised estimated remaining development period. There have been no other material changes to our critical accounting policies and estimates discussed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014.
Fair Value Of Financial Instruments	Fair Value of Financial Instruments
	Assets and liabilities measured at fair value on a recurring basis
	The following table sets forth the fair value of our financial assets and liabilities measured on a recurring basis as of March 31, 2015 and December 31, 2014:
	(in thousands)	31-Mar-15										31-Dec-14
		Level 1			Level 2			Level 3		Total		Level 1		Level 2		Level 3		Total
	Assets
	Cash and cash equivalents:
	Cash and money market funds	$	9,799		$	—		$	—	$	9,799	$	21,952	$	—	$	—	$	21,952
	Commercial paper		—			20,472			—		20,472		—		14,497		—		14,497
	Total cash and cash equivalents		9,799			20,472			—		30,271		21,952		14,497		—		36,449
	Investments:
	Commercial paper		—			24,953			—		24,953		—		43,653		—		43,653
	Corporate debt securities		—			8,149			—		8,149		—		8,173		—		8,173
	Asset backed securities		—			15,776			—		15,776		—		13,073		—		13,073
	Total investments		—			48,878			—		48,878		—		64,899		—		64,899
	Total assets measured at fair value	$	9,799		$	69,350		$	—	$	79,149	$	21,952	$	79,396	$	—	$	101,348
	Liabilities
	Financing derivative	$	—		$	—		$	863	$	863	$	—	$	—	$	944	$	944
	Our cash deposits and money market funds are classified within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. Our investments are classified as Level 2 instruments based on market pricing and other observable inputs. None of our investments are classified within Level 3 of the fair value hierarchy.
	During the three-month periods ended March 31, 2015 and 2014, there were no impairments of our investments.
	The estimated fair value of the Financing Derivative liability (as defined in Note 6. Notes Payable) was determined using Level 3 inputs, or significant unobservable inputs. Changes to the estimated fair value of the Financing Derivative are recorded in “Other income (expense), net” in the condensed consolidated statements of operations and comprehensive loss. The following table provides the changes in the estimated fair value of the Financial Derivative during the three-month period ended March 31, 2015 (in thousands):
	Financial Derivative	Amount
	Balance as of December 31, 2014	$	944
	Gain on change in estimated fair value		-81
	Balance as of March 31, 2015	$	863
	During the three-month period ended March 31, 2015 there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis and valuation techniques did not change compared to established practice.
	Financial assets and liabilities not measured at fair value on a recurring basis
	The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities. The carrying value of our other liabilities, non-current, approximates fair value due to the time to maturity and prevailing market rates.
	We determined the estimated fair value of the Notes (as defined in Note 6. Notes Payable) from the debt facility using Level 3 inputs, or significant unobservable inputs. The estimated fair value of the Notes was determined by comparing the difference between the estimated fair value of the Notes with and without the Financing Derivative by calculating the respective present values from future cash flows using an 18.4% and 19.5% weighted average market yield at March 31, 2015 and December 31, 2014, respectively.
	The estimated fair value and carrying value of the Notes are as follows (in thousands):
		31-Mar-15						31-Dec-14
		Fair Value			Carrying Value			Fair Value		Carrying Value
	Long-term notes payable	$	15,210		$	14,339		$	14,817	$	14,124
Net Loss Per Share	Net Loss per Share
	The following table presents the computation of our basic and diluted net loss per share (in thousands, except per share amounts):
			Three-Month Periods Ended March 31,
			2015			2014
	Net loss per share
	Numerator:
	Net loss		$	-20,173		$	-18,886
	Denominator:
	Weighted average shares used in computation of basic and diluted net loss per share			74,149			67,861
	Basic and diluted net loss per share		$	-0.27		$	-0.28
	The following were excluded from the computation of our diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect:
		As of March 31,
	(in thousands)	2015		2014
	Options outstanding	18,796		15,714
	Warrants to purchase common stock	5,500		5,500
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2014-09, Revenue from Contracts with Customers, requiring entities to recognize revenue to which it expects to be entitled for the transfer of promised goods or services to customers.  The updated standard will replace most existing revenue recognition guidance in GAAP when it becomes effective and permits the use of either a retrospective or cumulative effect transition method. The updated standard is effective for the Company in the first quarter of fiscal year 2017 and early adoption is not permitted. We are currently in the process of evaluating the impact of adopting this ASU on our financial statements and related disclosures.
	In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This ASU introduces an explicit requirement for management to assess if there is substantial doubt about an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. Disclosures are required if conditions give rise to substantial doubt. This ASU is effective for us in the first quarter of fiscal year 2017. We are currently in the process of evaluating the impact of adopting this ASU on our financial statements and related disclosures.
	In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs,  which changes the presentation of debt issuance costs in financial statements. This ASU requires an entity to present such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs will continue to be reported as interest expense. This ASU is effective for the Company’s annual report periods beginning after December 15, 2016 and is effective for us in the first quarter of fiscal year 2016. Early adoption is permitted. The new guidance will be applied retrospectively to each prior period presented. We are currently in the process of evaluating the impact of adopting this ASU on our financial statements and related disclosures.

Summary_Of_Significant_Account2

Summary Of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2015
Summary Of Significant Accounting Policies [Abstract]
Summary Of Assets And Liabilities Measured At Fair Value Classified Based On Level Of Input
	(in thousands)	31-Mar-15										31-Dec-14
		Level 1			Level 2			Level 3		Total		Level 1		Level 2		Level 3		Total
	Assets
	Cash and cash equivalents:
	Cash and money market funds	$	9,799		$	—		$	—	$	9,799	$	21,952	$	—	$	—	$	21,952
	Commercial paper		—			20,472			—		20,472		—		14,497		—		14,497
	Total cash and cash equivalents		9,799			20,472			—		30,271		21,952		14,497		—		36,449
	Investments:
	Commercial paper		—			24,953			—		24,953		—		43,653		—		43,653
	Corporate debt securities		—			8,149			—		8,149		—		8,173		—		8,173
	Asset backed securities		—			15,776			—		15,776		—		13,073		—		13,073
	Total investments		—			48,878			—		48,878		—		64,899		—		64,899
	Total assets measured at fair value	$	9,799		$	69,350		$	—	$	79,149	$	21,952	$	79,396	$	—	$	101,348
	Liabilities
	Financing derivative	$	—		$	—		$	863	$	863	$	—	$	—	$	944	$	944
Changes In Fair Value Of Financial Derivative
	Financial Derivative	Amount
	Balance as of December 31, 2014	$	944
	Gain on change in estimated fair value		-81
	Balance as of March 31, 2015	$	863
Estimated Fair Value And Carrying Value of Notes
		31-Mar-15						31-Dec-14
		Fair Value			Carrying Value			Fair Value		Carrying Value
	Long-term notes payable	$	15,210		$	14,339		$	14,817	$	14,124
Computation Of Basic And Diluted Net Loss Per Share
			Three-Month Periods Ended March 31,
			2015			2014
	Net loss per share
	Numerator:
	Net loss		$	-20,173		$	-18,886
	Denominator:
	Weighted average shares used in computation of basic and diluted net loss per share			74,149			67,861
	Basic and diluted net loss per share		$	-0.27		$	-0.28
Anti-dilutive Excluded From Computation Of Diluted Net Loss Per Share
		As of March 31,
	(in thousands)	2015		2014
	Options outstanding	18,796		15,714
	Warrants to purchase common stock	5,500		5,500

Cash_Cash_Equivalents_And_Inve1

Cash, Cash Equivalents And Investments (Tables)	3 Months Ended
	Mar. 31, 2015
Cash, Cash Equivalents And Investments [Abstract]
Summary Of Cash, Cash Equivalents And Investments
		31-Mar-15
				Gross		Gross
		Amortized		unrealized		unrealized		Fair
		Cost		gains		losses		Value
	Cash and cash equivalents:
	Cash and money market funds	$	9,799	$	—	$	—	$	9,799
	Commercial paper		20,471		1		—		20,472
	Total cash and cash equivalents		30,270		1		—		30,271
	Investments:
	Commercial paper		24,950		3		—		24,953
	Corporate debt securities		8,138		11		—		8,149
	Asset backed securities		15,775		2		-1		15,776
	Total investments		48,863		16		-1		48,878
	Total cash, cash equivalents and investments	$	79,133	$	17	$	-1	$	79,149
		31-Dec-14
				Gross		Gross
		Amortized		unrealized		unrealized		Fair
		Cost		gains		losses		Value
	Cash and cash equivalents:
	Cash and money market funds	$	21,952	$	—	$	—	$	21,952
	Commercial paper		14,496		1		—		14,497
	Total cash and cash equivalents		36,448		1		—		36,449
	Investments:
	Commercial paper		43,648		5		—		43,653
	Corporate debt securities		8,170		7		-4		8,173
	Asset backed securities		13,073		4		-4		13,073
	Total investments		64,891		16		-8		64,899
	Total cash, cash equivalents and investments	$	101,339	$	17	$	-8	$	101,348
Summary Of Contractual Maturities Of Cash Equivalents And Available-For-Sale Investments
	(in thousands)	Fair Value
	Due in one year or less	$	69,350

Inventory_Tables

Inventory (Tables)	3 Months Ended
	Mar. 31, 2015
Inventory [Abstract]
Components Of Inventory
		March 31,		December 31,
	(in thousands)	2015		2014
	Purchased materials	$	2,064	$	3,150
	Work in process		9,751		6,115
	Finished goods		1,642		2,070
	Inventory	$	13,457	$	11,335

Stockholders_Equity_And_ShareB1

Stockholders' Equity And Share-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity And Share-Based Compensation [Abstract]
Summary Of Stock Option Activity
				Stock Options Outstanding
								Weighted
		Shares available		Number				average
		for grant		of shares		Exercise price		exercise price
	Balances, December 31, 2014	4,874		16,491		$	0.70 – 16.00	$	5.10
	Additional shares reserved	4,435
	Options granted	-2,474		2,474			5.72 – 7.59		6.55
	Options exercised	—		-72			0.70 – 5.18		2.40
	Options canceled	97		-97			1.16 – 15.98		6.63
	Balances, March 31, 2015	6,932		18,796		$	0.70 – 16.00	$	5.30
Schedule Of Stock-Based Compensation Expense
		Three-Month Periods Ended March 31,
		2015			2014
	Cost of revenue	$	298		$	141
	Research and development		1,255			886
	Sales, general and administrative		1,702			1,243
	Total stock-based compensation expense	$	3,255		$	2,270
Schedule Of Fair Value Of Employee Stock Options
		Three-Month Periods Ended March 31,
	Stock Option	2015		2014
	Expected term in years	6.1		6.1
	Expected volatility	70%		70%
	Risk-free interest rate	1.60%		1.90%
	Dividend yield	—		—
Schedule Of Fair Value Of Employee Stock Purchase Plan
		Three-Month Periods Ended March 31,
	ESPP	2015		2014
	Expected term in years	0.5-2.0		0.5-2.0
	Expected volatility	70%		70%
	Risk-free interest rate	0.1%-0.6%		0.1%-0.3%
	Dividend yield	—		—

Summary_Of_Significant_Account3

Summary Of Significant Accounting Policies (Narrative) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Summary Of Significant Accounting Policies [Abstract]
Impairment charges on investments	$0	$0
Fair value assets liabilities transfer between levels	$0
Future cash flows weighted average market yield	18.40%		19.50%

Summary_Of_Significant_Account4

Summary Of Significant Accounting Policies (Summary Of Assets And Liabilities Measured At Fair Value Classified Based On Level Of Input) (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Assets
Total assets measured at fair value	$79,149	$101,348
Financing Derivative [Member]
Liabilities
Total liabilities measured at fair value	863	944
Cash and cash equivalents [Member]
Assets
Total cash and cash equivalents	30,271	36,449
Cash and cash equivalents [Member] | Cash and money market funds [Member]
Assets
Total cash and cash equivalents	9,799	21,952
Cash and cash equivalents [Member] | Commercial paper [Member]
Assets
Total cash and cash equivalents	20,472	14,497
Investments [Member]
Assets
Total investments	48,878	64,899
Investments [Member] | Commercial paper [Member]
Assets
Total investments	24,953	43,653
Investments [Member] | Corporate debt securities [Member]
Assets
Total investments	8,149	8,173
Investments [Member] | Asset backed securities [Member]
Assets
Total investments	15,776	13,073
Level 1 [Member]
Assets
Total assets measured at fair value	9,799	21,952
Level 1 [Member] | Cash and cash equivalents [Member]
Assets
Total cash and cash equivalents	9,799	21,952
Level 1 [Member] | Cash and cash equivalents [Member] | Cash and money market funds [Member]
Assets
Total cash and cash equivalents	9,799	21,952
Level 2 [Member]
Assets
Total assets measured at fair value	69,350	79,396
Level 2 [Member] | Cash and cash equivalents [Member]
Assets
Total cash and cash equivalents	20,472	14,497
Level 2 [Member] | Cash and cash equivalents [Member] | Commercial paper [Member]
Assets
Total cash and cash equivalents	20,472	14,497
Level 2 [Member] | Investments [Member]
Assets
Total investments	48,878	64,899
Level 2 [Member] | Investments [Member] | Commercial paper [Member]
Assets
Total investments	24,953	43,653
Level 2 [Member] | Investments [Member] | Corporate debt securities [Member]
Assets
Total investments	8,149	8,173
Level 2 [Member] | Investments [Member] | Asset backed securities [Member]
Assets
Total investments	15,776	13,073
Level 3 [Member]
Assets
Total assets measured at fair value
Level 3 [Member] | Financing Derivative [Member]
Liabilities
Total liabilities measured at fair value	863	944
Level 3 [Member] | Cash and cash equivalents [Member]
Assets
Total cash and cash equivalents
Level 3 [Member] | Cash and cash equivalents [Member] | Cash and money market funds [Member]
Assets
Total cash and cash equivalents
Level 3 [Member] | Cash and cash equivalents [Member] | Commercial paper [Member]
Assets
Total cash and cash equivalents
Level 3 [Member] | Investments [Member]
Assets
Total investments
Level 3 [Member] | Investments [Member] | Commercial paper [Member]
Assets
Total investments
Level 3 [Member] | Investments [Member] | Corporate debt securities [Member]
Assets
Total investments
Level 3 [Member] | Investments [Member] | Asset backed securities [Member]
Assets
Total investments

Summary_Of_Significant_Account5

Summary Of Significant Accounting Policies (Changes In Fair Value Of Financial Derivative) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Summary Of Significant Accounting Policies [Abstract]
Balance as of December 31, 2014	$944
Gain on change in estimated fair value	-81
Balance as of March 31, 2015	$863

Summary_Of_Significant_Account6

Summary Of Significant Accounting Policies (Estimated Fair Value And Carrying Value Of Notes) (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Fair Value [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Long-term notes payable	$15,210	$14,817
Carrying Value [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Long-term notes payable	$14,339	$14,124

Summary_Of_Significant_Account7

Summary Of Significant Accounting Policies (Computation Of Basic And Diluted Net Loss Per Share) (Details) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Numerator:
Net loss	($20,173)	($18,886)
Denominator:
Weighted average shares used in computation of basic and diluted net loss per share	74,149	67,861
Basic and diluted net loss per share	($0.27)	($0.28)

Summary_Of_Significant_Account8

Summary Of Significant Accounting Policies (Anti-dilutive Excluded From Computation Of Diluted Net Loss Per Share) (Details)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Stock excluded from the computation of diluted net loss per share	18,796	15,714
Warrants to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Stock excluded from the computation of diluted net loss per share	5,500	5,500

Contractual_Revenue_Details

Contractual Revenue (Details) (USD $)	3 Months Ended	1 Months Ended		3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2014	Aug. 31, 2014	Sep. 30, 2013	Mar. 31, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue, revenue recognized	$1.70
Roche Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Non-refundable upfront payment			35
Additional contractual revenue being recognized in the period				1.9
Deferred revenue, revenue recognized				3.6
Deferred revenue				22.9
Loss per share				($0.03)
Maximum potential for additional payments to be recognized upon the achievement of certain development milestones			40
Additional payment based upon achievements of milestones		$10

Cash_Cash_Equivalents_And_Inve2

Cash, Cash Equivalents And Investments (Summary Of Cash And Cash Equivalents And Investments) (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$79,133	$101,339
Gross unrealized gains	17	17
Gross unrealized losses	-1	-8
Fair Value	79,149	101,348
Cash and cash equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	30,270	36,448
Gross unrealized gains	1	1
Fair Value	30,271	36,449
Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	48,863	64,891
Gross unrealized gains	16	16
Gross unrealized losses	-1	-8
Fair Value	48,878	64,899
Cash and money market funds [Member] | Cash and cash equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	9,799	21,952
Fair Value	9,799	21,952
Commercial paper [Member] | Cash and cash equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	20,471	14,496
Gross unrealized gains	1	1
Fair Value	20,472	14,497
Commercial paper, not included with cash and cash equivalents [Member] | Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	24,950	43,648
Gross unrealized gains	3	5
Fair Value	24,953	43,653
Corporate debt securities [Member] | Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	8,138	8,170
Gross unrealized gains	11	7
Gross unrealized losses		-4
Fair Value	8,149	8,173
Asset backed securities [Member] | Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	15,775	13,073
Gross unrealized gains	2	4
Gross unrealized losses	-1	-4
Fair Value	$15,776	$13,073

Cash_Cash_Equivalents_And_Inve3

Cash, Cash Equivalents And Investments (Summary Of Contractual Maturities Of Cash Equivalents And Available-For-Sale Investments) (Details) (USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
Cash, Cash Equivalents And Investments [Abstract]
Due in one year or less	$69,350

Inventory_Details

Inventory (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Inventory [Abstract]
Purchased materials	$2,064	$3,150
Work in process	9,751	6,115
Finished goods	1,642	2,070
Inventory	$13,457	$11,335

Notes_Payable_Details

Notes Payable (Details) (USD $)	1 Months Ended	3 Months Ended
	Feb. 28, 2013	Mar. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Purchase shares of common stock	5,500,000	5,500,000
Common stock aggregate exercise price	$2.63
Cash and cash equivalent minimum amount quarterly required	$2,000,000
Future cash flows weighted average market yield		18.40%	19.50%
Fair value of the financing derivative		863,000	944,000
Fair value of the notes	14,100,000
Fair value of the warrants	6,400,000
Allocation of notes calculated on a relative fair value basis	20,500,000
Notes carrying value		14,339,000	14,124,000
Carrying value of the notes	12,800,000
Original issue discount	7,700,000
Debt discount that has yet to be amortized		6,200,000	6,400,000
Maturity date		1-Feb-20
Deerfield promissory notes [Member]
Debt Instrument [Line Items]
Principal amount of notes	$20,500,000
Debt instrument, stated interest rate	8.75%

Stockholders_Equity_And_ShareB2

Stockholders' Equity And Share-Based Compensation (Narrative) (Details)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Feb. 28, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Purchase shares of common stock	5,500,000		5,500,000
Number of equity compensation plans	3
Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares issued	532,217	1,048,604
Common stock reserved for issuance	946,329

Stockholders_Equity_And_ShareB3

Stockholders' Equity And Share-Based Compensation (Summary Of Stock Option Activity) (Details) (Stock Options [Member], USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Additional shares reserved, Shares available for grant	4,435,000
$0.70 b 16.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balances, December 31, 2014, Shares available for grant		4,874,000
Balances, December 31, 2014, Number of shares		16,491,000
Exercise price, lower range		$0.70
Exercise price, upper range		$16
Balances, December 31, 2014, Weighted average exercise price per share		$5.10
$5.72 b 7.59 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options granted, Shares available for grant	-2,474,000
Options granted, Number of shares	2,474,000
Exercise price, lower range	5.72
Exercise price, upper range	7.59
Options granted, Weighted average exercise price per share	6.55
$0.70 b 5.18 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options exercised, Shares available for grant
Options exercised, Number of shares	-72,000
Exercise price, lower range	0.7
Exercise price, upper range	5.18
Options exercised, Weighted average exercise price per share	2.4
$1.16 b 15.98 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options canceled, Shares available for grant	97,000
Options canceled, Number of shares	-97,000
Exercise price, lower range	1.16
Exercise price, upper range	15.98
Options canceled, Weighted average exercise price per share	6.63
$0.70 b 16.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balances, December 31, 2014, Shares available for grant	6,932,000
Balances, December 31, 2014, Number of shares	18,796,000
Exercise price, lower range	0.7
Exercise price, upper range	16
Balances, December 31, 2014, Weighted average exercise price per share	5.3

Stockholders_Equity_And_ShareB4

Stockholders' Equity And Share-Based Compensation (Schedule Of Stock-Based Compensation Expense) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$3,255	$2,270
Cost of revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	298	141
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	1,255	886
Sales, general and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$1,702	$1,243

Stockholders_Equity_And_ShareB5

Stockholders' Equity And Share-Based Compensation (Schedule Of Fair Value Of Employee Stock Options And Employee Stock Purchase Plan) (Details)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years	6 years 1 month 6 days	6 years 1 month 6 days
Expected volatility	70.00%	70.00%
Risk-free interest rate	1.60%	1.90%
Dividend yield
Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected volatility	70.00%	70.00%
Risk-free interest rate, minimum	0.10%	0.10%
Risk-free interest rate, maximum	0.60%	0.30%
Dividend yield
Employee Stock Purchase Plan [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years	6 months	6 months
Employee Stock Purchase Plan [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years	2 years	2 years

Subsequent_Event_Details

Subsequent Event (Details) (Roche Agreement [Member], USD $)	1 Months Ended
In Millions, unless otherwise specified	Aug. 31, 2014	Apr. 30, 2015	Sep. 30, 2013
Subsequent Event [Line Items]
Additional payment based upon achievements of milestones	$10
Maximum potential for additional payments to be recognized upon the achievement of certain development milestones			40
Subsequent Event [Member]
Subsequent Event [Line Items]
Additional payment based upon achievements of milestones		10
Maximum potential for additional payments to be recognized upon the achievement of certain development milestones		$20